Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Friday. They currently have a $8.50 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 115.74% from the stock’s current price.
The analysts wrote, “Valuation and impediments to achieving price target. We reiterate our Buy rating and are increasing our price target to $8.50 from $6. The drivers to our valuation change include: (1) adjustment to base year; (2) adjustment to fully diluted share count (negative impact, but no warrants, preferred shares, or debt); (3) adjusting our projected launch year for 2028 based on visibility of clinical hold lifting; and (4) increasing our projected chances of success for to 25%.””
A number of other analysts have also recently weighed in on the stock. ValuEngine cut shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. Zacks Investment Research lowered shares of Aptose Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, May 16th. Finally, Roth Capital set a $6.00 price target on shares of Aptose Biosciences and gave the stock a “buy” rating in a research report on Monday, April 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $6.25.
APTO opened at $3.94 on Friday. The firm has a market capitalization of $126.30 million, a P/E ratio of -7.58 and a beta of 2.37. Aptose Biosciences has a 12-month low of $1.15 and a 12-month high of $4.55.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its earnings results on Thursday, May 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.11). equities analysts predict that Aptose Biosciences will post -0.72 EPS for the current fiscal year.
An institutional investor recently bought a new position in Aptose Biosciences stock. Ladenburg Thalmann Financial Services Inc. purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 60,000 shares of the biotechnology company’s stock, valued at approximately $190,000. Ladenburg Thalmann Financial Services Inc. owned about 0.19% of Aptose Biosciences as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.45% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.